The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

EMA's CHMP has recommended AstraZeneca's Imfinzi for approval in the EU as a single agent for limited-stage small cell lung ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

The Business Research Company's Imfinzi (durvalumab) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib) and ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in ...

Imfinzi (durvalumab) was recommended by NICE for NHS use in combination with etoposide plus either carboplatin or cisplatin for adults with untreated extensive-stage small cell lung cancer (ES-SCLC).